Skip to content
Medical Health Aged Care

Curia Releases 2024 Environmental, Social and Governance (ESG) Report

Curia Global, Inc. 2 mins read

ALBANY, N.Y., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced the release of its third Environmental, Social and Governance (ESG) report. This latest report highlights the company’s new “C.U.R.I.A. Way” values—curiosity, urgency, respect, integrity and accountability—and how those values are woven into its mission, purpose and corporate responsibility initiatives.

Key accomplishments from the report include:

  • In 2024, Curia committed to setting near-and long-term company-wide GHG emission reductions in line with climate science through the Science Based Target Initiative (SBTi) and joined the United Nations’ Race to Zero campaign, a global coalition of non-state entities working toward halving global emissions by 2030.
  • Curia’s French facilities in Bon Encontre and Tonneins achieved ISO 9001, 45001 and 14001 certifications, and its sites in Origgio and Rozzano, Italy, achieved ISO 45001 and 14001 certifications. The company’s EHS Management System continues to mirror ISO 14001 and 45001 standards across all sites.
  • 85% of Curia’s facilities exceeded one year without a recordable injury, with nine sites exceeding more than two years.
  • Employees voluntarily devoted over 10,000 hours to learning on the company’s iLearn platform, powered by Skillsoft’s Percipio technology, which continues to offer learning resources for exempt-level employees globally.
  • Curia’s DE&I Council continues to expand with a focus on providing a forum for discussion and a path for advancement for all employees.

“Our latest ESG report reflects our progress as a leader in the industry from reducing our environmental footprint to fostering a culture of safety, integrity and responsibility,” said Philip Macnabb, CEO of Curia. “As Curia continues to evolve, we know there is still more work to be done. Our ESG initiatives remain deeply intertwined with our approach to scientific innovation and operational excellence as we serve our customers and their patients.”

To read the full ESG report, visit: https://curiaglobal.com/about-us/corporate-responsibility/

About Curia
Curia is a contract research, development and manufacturing organization (CDMO) with over 30 years of experience, an integrated network of 20+ global sites and 3,200 employees, partnering with biopharmaceutical customers to bring life-changing therapies to market. Our offerings in small molecule, generic APIs and biologics span discovery through commercialization, with integrated regulatory, analytical and sterile fill-finish capabilities. Our scientific and process experts, along with our regulatory compliant facilities, provide a best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate your research and improve patients’ lives. Visit us at curiaglobal.com.

Corporate Contact:
Viana Bhagan
Curia
+1 518 512 2111
[email protected]



Primary Logo

More from this category

  • Medical Health Aged Care
  • 22/01/2026
  • 23:11
Concept Medical Inc.

Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES

TAMPA, Fla.–BUSINESS WIRE– Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrollment of the first…

  • Contains:
  • Medical Health Aged Care
  • 22/01/2026
  • 22:11
Sinovac Biotech Ltd.

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

BEIJING--BUSINESS WIRE-- Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies. Under the Panel’s decision, SINOVAC must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and…

  • Medical Health Aged Care
  • 22/01/2026
  • 17:11
Galderma

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.